Optimisation and validation of immunohistochemistry protocols for cancer research

Authors: Peter Ella-tongwiis, Alexander Makanga, Iqbal Shergill and Stephen Fôn Hughes

DOI: 10.14670/HH-18-317
Article type: ORIGINAL ARTICLE
Accepted: 2021-02-22
Epub ahead of print: 2021-02-22
Optimisation and validation of immunohistochemistry protocols for cancer research

Peter Ella-tongwiis (PET)\textsuperscript{a,b,c}, Alexander Makanga (AM)\textsuperscript{b,d}, Iqbal Shergill (IS)\textsuperscript{a,b,c,e}, Stephen Fôn Hughes (SFH)\textsuperscript{a,b,c}\textsuperscript{*}

\textsuperscript{a}North Wales & North West Urological Research Centre, Betsi Cadwaladr University Health Board (BCUHB) Wrexham Maelor Hospital, Wrexham, Wales, UK

\textsuperscript{b}North Wales Clinical Research Centre, Betsi Cadwaladr University Health Board (BCUHB) Wrexham Maelor Hospital, Wrexham, Wales, UK

\textsuperscript{c}Faculty of Social and Life Sciences, Wrexham Glyndwr University, Wrexham, UK

\textsuperscript{d}Department of Histopathology, BCUHB Glan Clwyd Hospital, Denbighshire, Wales, UK

\textsuperscript{e}The Alan de Bolla Department of Urology, BCUHB Wrexham Maelor Hospital, Wrexham, Wales, UK

\textsuperscript{*}Corresponding author:

Stephen.hughes6@wales.nhs.uk (Stephen Fôn Hughes)
Abstract

Background
Immunohistochemistry (IHC) has become a valuable laboratory technique for diagnosing, evaluating metastasis and informing treatment selection in several cancers. Standardization however remains a limiting factor in IHC. The main aim of this research study was to optimise, validate and standardize antibodies and IHC protocols for cancer research.

Methods
Seven monoclonal mouse and rabbit antibodies were optimised using formalin-fixed paraffin embedded (FFPE) human tissue blocks. 4um sections of FFPE block were stained using the Roche Ventana XT or Ventana ULTRA IHC automated analysers. This study modified manufacturer recommended protocols by using a unique antigen retrieval method, adding an amplification step, varying primary antibody incubation times, as well as using the Roche Ventana Ultraview detection system.

Results
Optimum antibody localisation was observed in modified IHC protocols in comparison with manufacturer recommended protocols for anti-CEACAM-1, anti-CD31, anti-COX-2, anti-HER-2/neu, anti-S100P, anti-thrombomodulin and anti-VEGFR-3. Majority of antibodies required more than one modification of the initial protocol. For anti-VEGFR-3 optimum staining was observed following 4 protocol modifications.

Conclusions
This study has optimised and standardized several tissue-based biomarkers that may be, in the future, used to screen, diagnose and monitor patients with certain cancer, such as bladder cancer. Accurate data on optimised protocols reduce time and resources wasted on experimental protocols, and
ultimately help identify biomarkers or biomarker panels, which may be used to select treatment regimens for various cancers.

**Key Words:** Immunohistochemistry (IHC), Pathology, Angiogenesis, Cancer, Antibodies.

**Introduction**

Immunohistochemistry (IHC) is has become an important tool for differential diagnosis in cancer and also aids subsequent treatment selection. In breast cancer for example, IHC evaluation of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 (HER-2), provides valuable information in deciding treatment options (Dede et al., 2013; Xu et al., 2018). In bladder cancer, IHC is a potential tool for sub-classifying T1 tumours (Mhawech et al., 2002) and can also be used to highlight histological characteristics in various disorders of the bladder (Rajcani et al., 2013).

Research into biomarkers such as CEACAM-1, CD31, COX-2, HER-2, S100P, thrombomodulin and VEGFR-3 has produced varying results. Although CEACAM-1 is physiologically expressed in endothelial cells, epithelial cells and myeloid cells of several human organ systems (Kilic et al., 2005), it has also been associated with increased vascularisation of the chorioallantoic membrane. Furthermore, increased VEGF, a known pro-angiogenic factor, induces CEACAM-1, highlighting its link with tumour angiogenesis (Ergün et al., 2000). CD31, another marker of angiogenesis, is mainly localised on the surfaces of neutrophils, monocytes, platelets and endothelial cells (Stockinger et al., 1990; Righi et al., 2003). It may be secreted, membrane bound or localised intracellularly but it is most importantly utilised as a marker of angiogenesis by evaluating its immunoreactivity on blood vessel endothelium (Deliu et al., 2016; Qian et al., 2018).

Cyclooxygenase-2 (COX-2) is highly expressed in high stage and high grade colonic adenocarcinoma (Hedaya et al., 2015) and can therefore be used as a marker for diagnosis or exploited in the
development of treatment therapies. Thrombomodulin, a membrane receptor expressed on endothelial cells, has important roles in physiological coagulation (Esmon et al., 1982), inflammation and cancer promotion and proliferation (Wu et al., 2014; Greineder et al., 2017). The S100 proteins are associated with roles in cellular processes like regulation of cell cycle, growth, transcription and differentiation (Jiang et al., 2016). These proteins may be localised in different cellular compartments and are activated through calcium activation. The association between S100P and cellular processes such as cell survival, proliferation, tumour invasion and angiogenesis have been studied by various researchers (Guo et al., 2014; Liu et al., 2017; Tabrizi et al., 2018).

In order to precisely determine cancer diagnosis, progression or prognosis, clinicians rely on suitably researched biomarkers (O’Hurley et al., 2014). However, inter-laboratory variations due to sample collection and processing, antibody selection, detection systems and stain interpretation has led to difficulties in standardising IHC results across various pathology laboratories (Kirkegaard et al., 2006).

The main aim of this research study was to optimise, validate and standardize antibodies (anti-CEACAM-1, anti-CD31, anti_COX-2, anti-HER-2/neu, anti-S100P, anti-thrombomodulin and anti-VEGFR-3) and IHC protocols for evaluating cancers in the Histopathology Department. The data presented in this research study will provide valuable information for both researchers and practicing professionals, which may ultimately lead to the development of specific IHC platforms being created and utilised for clinical screening, diagnosis, and aiding treatment for several cancers.

Materials and Methods

**Ethical consideration and sample preparation**

Permission for this research study was sought from the Research Ethics Service (Reference: 14/WA/0033). Anonymised control FFPE tissue were kindly provided by the Histopathology Department of Betsi Cadwaladr University Health Board (BCUHB), Ysbyty Glan Clwyd Hospital, North
Wales (UK). All tissue samples were stained using either the Roche Ventana BenchMark ULTRA (Automated IHC/ISH slide staining system) or the Roche Ventana BenchMark XT (Automated IHC/ISH slide staining system). The NHS pathology department where this research was conducted is working towards ISO15189 accreditation and participates in UKNeqas testing schemes.

**Antibodies**

Monoclonal mouse anti-human CEACAM-1/CD66a, CD-31, S100P, thrombomodulin, VEGFR-3 and monoclonal rabbit anti-human COX-2, and HER-2/neu were investigated in this study. Antibodies were stored and treated according to manufacturer’s instructions. Table 1 summarises important information for each antibody optimised in this study. Other reagents used in this research include Ultraview universal DAB detection kit (Ventana medical systems; product number 760-500), amplification kit (Ventana medical systems; product no. 760-080), hematoxylin II (Ventana medical systems; product no 790-2208), Cell conditioning I (Ventana medical systems; product no 950-124), Cell conditioning II (Ventana medical systems; product no 950-123), EZ prep solution (Ventana medical systems; Product no. 950-102) and liquid coverslip (Ventana medical systems; product no 250-009).

**Table 1**: Details of antibody clones, suppliers and Immunohistochemical Staining localisations

<table>
<thead>
<tr>
<th>ANTIBODY (CLONE)</th>
<th>SUPPLIER</th>
<th>CONTROL TISSUES</th>
<th>LOCALISATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEACAM-1/CD66a</td>
<td>R&amp;D medical systems Europe Ltd</td>
<td>Colon</td>
<td>Cytoplasmic, membranous</td>
</tr>
<tr>
<td>(283324)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD31 (JC70)</td>
<td>Cell Marque (Sigma Aldrich, UK)</td>
<td>Placenta</td>
<td>Cytoplasmic, membranous</td>
</tr>
<tr>
<td>COX-2 (SP21)</td>
<td>Cell Marque (Sigma Aldrich, UK)</td>
<td>Colon</td>
<td>Cytoplasmic, membranous</td>
</tr>
<tr>
<td>HER-2/neu (4B5)</td>
<td>Roch diagnostics</td>
<td>Breast</td>
<td>membranous</td>
</tr>
<tr>
<td>S100P (16/f5)</td>
<td>Cell Marque (Sigma Aldrich, UK)</td>
<td>Placenta</td>
<td>Cytoplasmic, nuclear</td>
</tr>
<tr>
<td>Thrombomodulin (1009)</td>
<td>Cell Marque (Sigma Aldrich, UK)</td>
<td>Bladder</td>
<td>Cytoplasmic, membranous</td>
</tr>
</tbody>
</table>
| VEGFR-3/Flt-4    | R&D medical systems Europe Ltd | Umbilical cord   | Nuclear              | (54703)
Control tissues

FFPE Human Colon adenocarcinoma, Placenta, Breast Carcinoma, Fallopian Tube, Umbilical Cord, and Transitional Cell Carcinoma (TCC) Bladder were used for validating the various antibodies. These tissues were specifically selected because previous research has shown that CEACAM-1 is expressed in colon (Han et al., 2018), CD31 is expressed in human placenta (Shchegolev et al., 2016), COX-2 is expressed human colon (Wu et al., 2015), HER-2/neu is expressed in breast cancer (Gulzar et al., 2018), S100P is expressed in human placenta (Zhu et al., 2015), Thrombomodulin is expressed in human bladder (Chuang et al., 2007) and VEGFR-3 is expressed in human umbilical cord (Olaya-C et al., 2019).

Immunohistochemistry protocols

A modified indirect IHC used in a UKAS Accredited NHS Pathology Department was used to stain all tissue sections [Table 2]. Tissue slides were dewaxed by using 1X EZ prep solution (supplied by Ventana Medical Systems, UK), heat and vortex mixing. Heated paraffin wax floated out from tissue sections through the aqueous solution and was efficiently removed by vortex mixing. In the presence of heat, Cell Conditioning 1 (CC1-supplied by Ventana Medical Systems, UK) was used for antigen retrieval (heat induced epitope retrieval). The basic pH and tris-based buffer in CC1 enhances antibody binding in tissues, by hydrolysing covalent bonds at high temperature. Evaporation was minimized by using liquid cover slip (LCS) (Ventana Medical Systems, UK). This prevents tissue sections from drying up during the IHC. Liquid coverslip was applied between segments of IHC procedure.

Endogenous proteins and peroxides were blocked using Ventana diluent/option 1 for 4 minutes. Primary antibodies, which were mouse or rabbit monoclonal IgG antibodies, were applied to tissues sections and incubated at various durations (see optimised protocols). HRP-labelled secondary
antibodies (goat anti-mouse IgG, goat anti-mouse IgM, and goat anti-rabbit IgG) were then added to the slides.

Table 2: Standard IHC protocol versus the modified protocol used in this research (standard IHC protocol adapted from Taylor et al., 2013)

<table>
<thead>
<tr>
<th>Standard IHC protocol</th>
<th>Modified/Validated IHC protocol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deparaffinization/dewaxing</td>
<td>Deparaffinization/dewaxing</td>
</tr>
<tr>
<td>Antigen Retrieval</td>
<td>Antigen Retrieval</td>
</tr>
<tr>
<td>Blocking</td>
<td>Blocking</td>
</tr>
<tr>
<td>Primary Antibody</td>
<td>Primary Antibody</td>
</tr>
<tr>
<td>Secondary Antibody</td>
<td>Ventana ultraview DAB detection (plus secondary antibodies)</td>
</tr>
<tr>
<td>Colour development/Counterstain</td>
<td>Amplifier, Ultrawash</td>
</tr>
<tr>
<td>Colour development/Counterstain</td>
<td>Colour development/Counterstain</td>
</tr>
</tbody>
</table>

The detection kit used in this research; the Ventana Ultraview DAB universal detection kit (Ventana Medical Systems, UK) is an indirect biotin-free kit capable of identifying mouse and rabbit IgG and IgM antibodies in PPFE tissue sections. Following exposure to primary antibody and HRP-labelled secondary antibody, 3, 3’-diaminobenzidine (DAB) was used for colour development. DAB is catalysed to form a brown precipitate (oxidised form of DAB) in the presence of hydrogen peroxide. This is then visualised using light microscopy (Figure 1).

Ventana haematoxylin 1 was used as counterstain and stains nuclei blue by reacting with a dye complex in the presence of nucleic acids and histone proteins. Tissue sections were dehydrated and
mounted in DPX. For each IHC stain, both positive and negative control tissues were present on the slides. Additionally, negative control slides were added to each staining cycle by omitting the primary antibody.

![Diagram of Ventana Ultraview detection kit](https://example.com/diagram.png)

**Figure 1: Graphical representation of the Ventana Ultraview detection kit**

**Results**

**Optimisation of anti-CEACAM-1 primary monoclonal antibody reactivity in tissues using IHC**

CEACAM-1 exhibits membranous or cytoplasmic localisation in colonic epithelial cells. Three experimental protocols were analysed for optimum anti-CEACAM-1 staining in human colon adenocarcinoma tissue. Protocol 2 [summarised in Table 3] produced clear moderate staining intensity and had a shorter duration, less background staining and required an amplification step [Figure 2(A,B,C)].
Optimisation of anti-CD31 primary monoclonal antibody reactivity in tissues using IHC

CD31 exhibits membranous and cytoplasmic localisation in vascular endothelial cells in human placenta. Two modification of the recommended protocol were analysed for optimum anti-CD31 staining [Figure 3(A,B)].

Optimisation of COX-2 antibody immunoreactivity in tissues using IHC

Three variations of the protocol were used in optimising anti-COX-2 antibody. Optimum staining was achieved with protocol 2, which showed strong intensity staining with little background noise. Protocol 2 had 32 minutes primary antibody incubation and did not require amplification [Figure 4 (A,B,C)].

Optimisation of Anti HER-2/neu (4B5) monoclonal antibody

Figure 5(A, B, C) illustrate optimisation of Anti-HER-2/neu. The optimum protocol produced strong intensity membranous staining with a primary antibody incubation of 32 minutes, and an amplification step. IHC optimisation protocols for anti-S100P monoclonal antibody.

Strong intensity anti-S100P staining was observed in human placenta tissues increasing primary antibody incubation time and adding an amplification step to the protocol using ventana amplifier [Figure 6(A,B)].

Optimisation of anti-thrombomodulin primary monoclonal antibody

Anti-thrombomodulin staining in human bladder required two modification of the initial protocol. The optimised protocol had a blocking step, primary antibody incubation time of 32 minutes, an amplification step and an ultrawash step. These resulted in strong intense membraneous staining in epithelial cells within human bladder [Figure 7(A, B, C)].
Optimisation of anti-VEGFR-3 primary monoclonal antibody

Moderate IHC staining was achieved in protocol 4. Three other experimental protocols produced non-specific staining with high background noise in human umbilical cord sample [Figure 8(A,B,C,D)].

Table 3 Summary of optimised protocols for IHC. These protocols are modifications of manufacturer recommendation and produced optimum antibody staining in FFPE human control tissues. The modified IHC protocol used in this research has a unique and novel antigen retrieval method on the Roche Ventana XT and Ventana ultra IHC system(s). For all protocols, haematoxylin counter stain was applied for 12 minutes, blueing reagent was applied for 4 minutes and the ventana Ultraview DAB detection system was used.
Table 3: Summary of optimised protocols for IHC. These protocols are modifications of manufacturer recommendation and produced optimum antibody staining in FFPE human control tissues. The modified IHC protocol used in this research has a unique antigen retrieval method on the Roche Ventana XT and Ventana ultra IHC system(s). All protocols used a ventana Ultraview detection system, haematoxylin II counterstain was applied for 12 minutes followed by blueing reagent for 4 minutes.

<table>
<thead>
<tr>
<th>Control tissue</th>
<th>Optimised S100P protocol</th>
<th>Optimised COX-2 protocol</th>
<th>Optimised HER-2 protocol</th>
<th>Optimised VEGFR-3 protocol</th>
<th>Optimised CEACAM-1 protocol</th>
<th>Optimised CD31 protocol</th>
<th>Optimised Thrombomodulin protocol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control tissue</td>
<td>Placenta</td>
<td>Colon adenocarcinoma</td>
<td>Breast carcinoma</td>
<td>Umbilical cord</td>
<td>Colon</td>
<td>Placenta</td>
<td>Bladder</td>
</tr>
<tr>
<td>Deparaffinization</td>
<td>72°C for 4 minutes</td>
<td>72°C for 4 minutes</td>
<td>72°C for 4 minutes</td>
<td>72°C for 4 minutes</td>
<td>72°C for 4 minutes</td>
<td>72°C for 4 minutes</td>
<td>72°C for 4 minutes</td>
</tr>
<tr>
<td>Antigen retrieval</td>
<td>Protease 1 for 8 minutes</td>
<td>CC1 95-100°C for 64 minutes</td>
<td>CC1 95-100°C for 4 minutes</td>
<td>CC1 at 100°C for 52 minutes</td>
<td>CC1 at 100°C for 36 minutes</td>
<td>CC1 at 100°C for 64 minutes</td>
<td>CC1 for 8 minutes</td>
</tr>
<tr>
<td>Blocking</td>
<td>Not required</td>
<td>Required</td>
<td>Ultra block with Ventana diluent</td>
<td>Ventana diluent</td>
<td>Ventana diluent</td>
<td>Not required</td>
<td>Ventana diluent</td>
</tr>
<tr>
<td>Primary antibody incubation at 37°C</td>
<td>24 minutes</td>
<td>32 minutes</td>
<td>20 minutes</td>
<td>16 Minutes (1:200 dilution)</td>
<td>8 Minutes (1:100 dilution)</td>
<td>32 Minutes</td>
<td>32 minutes</td>
</tr>
<tr>
<td>Amplification step</td>
<td>Amplifier required</td>
<td>Amplifier not required</td>
<td>Amplifier required</td>
<td>Ultrawash</td>
<td>Amplifier required</td>
<td>Amplifier required</td>
<td>Amplifier &amp; Ultrawash required</td>
</tr>
</tbody>
</table>
Discussion

The main aim of this study was to optimise IHC protocols and antibodies (CEACAM-1, CD31, COX-2, HER-2, S100P, thrombomodulin and VEGFR-3) that may provide standardized information used for assessing IHC staining of various antibodies in cancer research. Internal quality control was enhanced by including both control and sample tissues on the same IHC microscope slide.

Optimisation of the S100P antibody required an increased primary antibody incubation time, a post-stain amplification step was included and duration of counterstaining was increased to 12 minutes. The positive nuclear and cytoplasmic staining and reduced background staining, in trophoblastic epithelial cells of the human placenta control tissue complements other studies (Maciejczyk et al., 2013). Our study, however, requires a shorter primary antibody incubation time (24 minutes), shorter antigen retrieval (8 minutes) and a shorter overall IHC process compared to the process reported by others (Surowiak et al., 2007; Maciejczyk et al., 2013) and could be used as an alternative methodology for assessing anti-S100P immunoreactivity in BC tissues.

Anti-VEGFR-3 optimisation produced generally unspecific nuclei and cytoplasmic staining within normal endothelial cells, muscle tissue and other underlying stromal cells. Other researchers have observed non-specific staining in 4 clones of VEGFR-3 (Smith et al., 2010). With respect to the present study, the protocol was performed on umbilical cord samples in contrast with breast and colorectal cancers used by others (Smith et al., 2010), providing further application for staining of this biomarker in other tissue sample types.

Although previous studies have assessed COX-2 IHC staining in human endometrial carcinoma and colorectal cancer tissues (Hedaya et al., 2015; Cai et al., 2017), optimisation results from this present
study provides a new and novel method for performing IHC in human BC tissues. In contrast to others who used an EDTA buffer antigen retrieval method (Hedaya et al., 2015), the COX-2 antibody and IHC process used in this research study used a tris-based Heat Induced Epitope Retrieval (HIER) method for optimum staining. We provide further details of the staining process, sample micrographs of staining intensity, control and staining duration for optimum staining. This new approach and method for staining tissue COX-2, will help standardize future research protocols for those operators using the Roche Ventana XT IHC autostainer or the Roche Ventana ultra IHC autostainer platforms.

With regards to CEACAM-1, although the experimental protocols produced few overall variations, the optimum staining in human colon tissues was observed in experimental protocol 2. Previous research by Thom et al. (2009), reported a longer IHC protocol (2 days) and used only negative controls in contrast with our present study, which has a shorter protocol (3 hours). The CEACAM-1 IHC method developed in the present study, significantly reduces the protocol assay duration (2 days vs 3 hours) compared to the original method as described by Thom et al. (2009), and furthermore provides more detailed information about the staining patterns in control tissues.

Using breast adenocarcinoma tissue samples, the optimised protocol for HER-2/neu had an antigen retrieval time of 36 minutes, primary antibody incubation time was 20 minutes, and an amplification step was also included. HER-2 IHC is currently used for clinical management of invasive breast cancer, and has therefore been studied by other research groups (Shirsat et al., 2012; Ji et al., 2014). However, the present study provides new information with regards to staining Bladder Cancer (BC) tissues using the Roche Ventana XT IHC autostainer and the Roche Ventana ultra IHC autostainer platforms.

With the inclusion of an amplification step and an increased incubation time, optimum CD31 staining was observed within vascular endothelial cells in placenta tissues. The modified protocol for assessing
CD31 used in this research, therefore, may provide an alternative method for future researchers and will aid standardization of IHC protocols within pathology (clinical and research) laboratories.

Non-specific binding of anti-thrombomodulin was prevented by adding a blocking step, increasing primary antibody incubation time and adding an amplification step. These modifications produced enhanced membranous and cytoplasmic staining within Bladder epithelial cells as also reported by others (Song et al., 2018). In contrast to this present study however, the study by Song et al. (2018) does not provide any information on control tissues, stain protocol and protocol duration.

The optimised anti-VEGFR-3 antibody protocol produced nuclear staining patterns in fallopian tube tissues and complements results from a study by Capatina et al., (2019) who also reported similar staining patterns. In comparison with Capatina et al., (2019) however, the protocol developed in this current study had a shorter overall duration and is more suitable for BC research. Furthermore, this current research provides new information with regards staining BC tissues using the Roche Ventana XT IHC autostainer and the Roche Ventana ultra IHC autostainer platforms.

Variation in IHC may be caused by several factors and is one main source of controversy limiting standardisation across laboratories, research groups and regulatory bodies. Although storage duration of FFPE tissues has been highlighted as a potential source of variation, (Shi et al., 2007) have recommended the need to optimise antigen retrieval techniques prior to staining sample tissues.

In this study, validation of IHC protocols was performed by using manufacturer recommended protocols as a foundation for cancer research. Several FFPE tissue sections from control tissues (table 1) were stained using manufacturer recommended protocols. Following initial assessment by experienced pathologists/histopathologists, modification of the initial protocols were performed until optimised staining was achieved.
We acknowledge a limiting factor of this study was that only one clone per antibody was optimised and validated. There is therefore scope to perform further studies using other antibody clones and the present study provides a sound foundation to undertake such investigations.

A possible future direction for the present study is that the data obtained from this study, if standardized across laboratories, may be used as template in bladder cancer research. In future, this data may also be used for large studies in other cancers using FFPE tissue blocks. In summary, this study provides a sound platform for continued work in this area which will no doubt help contribute new knowledge and IHC protocol development involving cancer research.

In conclusion, the present study has optimised biomarker tissue staining methods that may be, in the future, used to validate and standardize IHC protocols for routine use or cancer research. Accurate data on optimised protocols reduce time and resources wasted on experimental protocols and ultimately help identify biomarkers or biomarker panels which may be used to select treatment regimens for various cancers.

Acknowledgments

The authors wish to thank all the staff at the Department of Histology at Betsi Cadwaladr University Health Board (BCUHB), Ysbyty Glan Clwyd, North Wales, UK, for their support regards our continued research activities.

Disclosure statement

No potential conflict of interest was reported by the authors.
Funding
The authors thankfully acknowledge BCUHB Department of Research & Innovation for their financial support.

Author details

\(^a\)North Wales & North West Urological Research Centre, Betsi Cadwaladr University Health Board (BCUHB) Wrexham Maelor Hospital, Wrexham, Wales, UK. \(^b\)North Wales Clinical Research Centre, Betsi Cadwaladr University Health Board (BCUHB) Wrexham Maelor Hospital, Wrexham, Wales, UK.

\(^c\)Faculty of Social and Life Sciences, Wrexham Glyndwr University, Wrexham, UK. \(^d\)Department of Histopathology, BCUHB Glan Clwyd Hospital, Denbighshire, Wales, UK. \(^e\)The Alan de Bolla Department of Urology, BCUHB Wrexham Maelor Hospital, Wrexham, Wales, UK.

ORCID

P Ella-tongwiis: [https://orcid.org/0000-0002-3049-7519](https://orcid.org/0000-0002-3049-7519)

SF Hughes: [https://orcid.org/0000-0001-6558-9037](https://orcid.org/0000-0001-6558-9037)
References


**Figures**

**Figure 1; Graphical representation of the Ventana Ultraview detection kit**

**Figure 2 (A,B,C):** Figure 2 (A, B, C): Optimisation of anti-CEACAM-1 antibody. (A). Negative control shows no membranous or cytoplasmic staining in human colon. (B). **Optimum membranous and cytoplasmic staining (moderate stain intensity)** in colon epithelial cells (brown). Deparaffinization- 72°C, CC1 at 100°C for 36 minutes, blocking- Option 1, Ab at 37°C for 8 Minutes (1:100 dilution), amplification step included (C). Manufacturer recommended protocol (moderate stain intensity) in colon epithelial cells (brown). Deparaffinization- 72°C, CC1 at 100°C for 36 minutes, blocking- Option 1, Ab at 37°C for 8 Minutes (1:200 dilution), amplification step included. Note: All protocols used detection kit- Optiview, counterstain (12 Minutes), blueing reagent (4 Minutes). X100 magnification

**Figure 3 (A,B):** Optimisation of anti-CD31 antibody. (A). Negative control shows no staining in human placenta samples. (B). Moderate intensity membranous and cytoplasmic staining in vascular endothelial cells (Red arrows) in human placenta tissue. Deparaffinization- 72°C for 4 minutes, CC1 at 100°C for 64 minutes, blocking- Not required, Anti CEACAM-1 Ab at 37°C for 32 minutes, amplification- not required, counterstain (12 Minutes), blueing reagent (4 Minutes), X100 magnification.

**Figure 4 (A,B,C):** Optimisation of Anti-COX-2 monoclonal antibody. (A). Negative control using human Colon adenocarcinoma. (B) (optimised protocol) Strong intensity cytoplasmic and membranous staining (red arrows)
in colonic crypts. Deparaffinization – 72°C for 4 minutes, Antigen retrieval - CC1 95 -100°C for 64 minutes, Ab incubation at 37°C for 32 minutes, Amplification- not required. (C). (manufacturer recommended) Strong intensity cytoplasmic and membranous staining in colonic crypts. Amplification step applied. Also note the deeper intensity and background staining. Note: All protocols used Detection kit- Ultraview. Counterstain for 12 minutes, blueing reagent (4 Minutes). X100 Magnification.

**Figure 5 (A,B,C): Optimisation of Anti-HER-2/neu monoclonal antibody.** (A). Negative control shows no staining in human breast carcinoma tissue. (B) (Manufacturer recommended) weak intensity membranous staining (blue arrows) in human breast carcinoma tissue using manufacturer settings. (C) (Optimised protocol). Strong intensity membranous staining seen in human breast carcinoma tissue (red arrows). Deparaffinization - 72°C for 4 minutes, antigen retrieval - CC1 95-100°C for 36 minutes, ultra-block with ventana diluent, antibody incubation at 37°C for 20 minutes, amplification- Ventana amplifier, detection kit- Ultraview, Counterstain for 12 minutes, blueing reagent (4 Minutes).

**Figure 6 (A,B): Optimisation of anti-S100P monoclonal antibody.** (A). Negative control shows no staining in human placenta. (B) (Optimised protocol). Strong intensity staining reported in human placenta. Deparaffinization – 72°C for 4 minutes, Antigen retrieval - Protease 1 for 8 minutes, Antibody incubation at 37°C for 24 minutes, Amplification step included, Detection kit- Ultraview, Counterstain for 12 minutes, blueing reagent (4 Minutes).

**Figure 7 (A,B,C): Optimisation of Anti-Thrombomodulin antibody (A).** Negative control shows no cytoplasmic or membranous staining in human bladder tissues. (B) (Manufacturer recommended) Moderate intensity membranous and cytoplasmic staining in Bladder tissue (Red arrows). Antibody incubation= 16 Minutes, no amplification, Ultrawash added, Ventana ultraview DAB detection. (C). (Optimised protocol) Strong intensity membranous and cytoplasmic staining seen in epithelial cells in human bladder tissue (Red arrows). Deparaffinization- 72°C for 4 minutes, antigen retrieval - CC1 for 8 minutes, blocking- Ventana option 1, Ab incubation at 37°C for 32 minutes, amplification- Ventana amplifier, Ultrawash step included. Note: All protocols used detection kit- Ultraview, counterstain for 12 minutes, blueing reagent (4 Minutes), X100 magnification.
Figure 8 (A,B,C,D): Optimisation of anti-VEGFR-3 antibody. (A). Negative control shows no staining. (B) (Manufacturer recommended) Strong intensity nuclear staining. Positive nuclear staining in endothelial cells (Red arrows). Note the strong nonspecific staining (blue arrows) within underlying stroma and muscle cell. (C) Strong intensity nuclear staining. Positive nuclear staining in endothelial cells (Red arrows). Note the reduced background staining compared to 3E. (D) (Optimised protocol). Moderate intensity nuclear staining in endothelial cells (brown). Note the significantly reduced nonspecific staining within underlying stroma and muscle cell. Deparaffinization- 72°C, CC1 at 100°C for 52 Minutes, Blocking- Ventana diluent, Ab incubation at 37°C for 16 Minutes (1:200 dilution), Ultrawash, detection kit- Ultraview, counterstain (12 Minutes), blueing reagent (4 Minutes).
**Standard IHC protocol**

1. Deparaffinization/dewaxing
2. Antigen Retrieval
3. Blocking
4. Primary Antibody
5. Secondary Antibody
6. Colour development/Counterstain

**Modified/Validated IHC protocol**

1. Deparaffinization/dewaxing
2. Antigen Retrieval
3. Blocking
4. Primary Antibody
5. Ventana ultraview DAB detection (plus secondary antibodies)
6. Amplifier, Ultrawash
7. Colour development/Counterstain
In the presence of HRP, DAB chromogen and $\text{H}_2\text{O}_2$, a brown precipitate is formed.

**HRP labelled secondary antibody**
Binds to primary antibody

**Specific primary antibody**
Binds to specific cell or tissue

**Cell or tissue**
Immobilised on glass slide

**IHC glass slide**